World-first pig kidney trials mark turning point for xenotransplantation
For decades, the promise of xenotransplantation — the transplantation of organs from animals into humans — has remained just beyond reach. The field has long been dogged by immunological rejection, concerns over viral transmission and ethical dilemmas1. But in February 2025, a pivotal moment was reached when the US Food and Drug Administration approved the first clinical trial testing whether kidneys from genetically modified pigs could be safely transplanted into humans. Until then, xenotransplantation had been limited to individual cases approved under compassionate use or expanded access protocols. This pathway allows patients with serious, life-threatening illnesses to access experimental treatments when no other comparable options are available. A first-in-human clinical trial could lay the foundation for xenotransplantation to become a routine medical treatment, potentially saving thousands of lives each year.
Access options
doi: https://doi.org/10.1038/d41591-025-00020-0
The Clinical Pipeline is a column on translational and clinical research, from bench to bedside.
Was this article displayed correctly? Not happy with what you see?
If you often open multiple tabs and struggle to keep track of them, Tabs Reminder is the solution you need. Tabs Reminder lets you set reminders for tabs so you can close them and get notified about them later. Never lose track of important tabs again with Tabs Reminder!
Try our Chrome extension today!
Share this article with your
friends and colleagues.
Earn points from views and
referrals who sign up.
Learn more
Save articles to reading lists
and access them on any device